EMCURE

Emcure Pharmaceuticals Share Price

 

 

Invest in Emcure Pharmaceuticals with 3.28X leverage

Invest with MTF

Performance

  • Low
  • ₹1,467
  • High
  • ₹1,550
  • 52 Week Low
  • ₹889
  • 52 Week High
  • ₹1,586
  • Open Price₹1,550
  • Previous Close₹1,535
  • Volume210,425
  • 50 DMA₹1,461.39
  • 100 DMA₹1,421.99
  • 200 DMA₹1,382.57

Investment Returns

  • Over 1 Month + 3.59%
  • Over 3 Month + 11.9%
  • Over 6 Month + 5.06%
  • Over 1 Year + 18.18%

Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!

Invest Now

Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 32.3
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 28,100
  • P/B Ratio
  • 5.9
  • Average True Range
  • 59.66
  • EPS
  • 47.73
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 14.42
  • RSI
  • 49.5
  • MFI
  • 61.81

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,482.30
-52.6 (-3.43%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹1,492.34
  • 50 Day
  • ₹1,461.39
  • 100 Day
  • ₹1,421.99
  • 200 Day
  • ₹1,382.57

Resistance and Support

1499.7 Pivot Speed
  • R3 1,615.80
  • R2 1,582.90
  • R1 1,532.60
  • S1 1,449.40
  • S2 1,416.50
  • S3 1,366.20

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Emcure Pharmaceuticals manufactures and markets a wide range of pharmaceutical products, including generics, biosimilars, and injectables. With a global presence in 70+ countries, it focuses on affordable healthcare solutions across therapeutic areas like cardiology, oncology, and women’s health.

Emcure Pharmaceuticals Ltd has an operating revenue of Rs. 8,449.23 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 12% is healthy, ROE of 15% is good. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 13% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 89 which is a GOOD score indicating consistency in earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Supplies and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-04 Quarterly Results
2025-11-11 Quarterly Results
2025-08-07 Quarterly Results
2025-05-22 Audited Results & Final Dividend
2025-02-06 Quarterly Results
Date Purpose Remarks
2025-08-14 FINAL Rs.3.00 per share(30%)Final Dividend
View Emcure Pharmaceuticals Dividend History Arrow

Emcure Pharmaceuticals F&O

Emcure Pharmaceuticals Shareholding Pattern

77.87%
4.83%
0.98%
3.59%
0%
6.45%
6.28%

About Emcure Pharmaceuticals

  • NSE Symbol
  • EMCURE
  • BSE Symbol
  • 544210
  • Managing Director & CEO
  • Mr. Satish Ramanlal Mehta
  • ISIN
  • INE168P01015

Similar Stocks to Emcure Pharmaceuticals

Emcure Pharmaceuticals FAQs

Emcure Pharmaceuticals share price is ₹1,482 As on 06 February, 2026 | 04:51

The Market Cap of Emcure Pharmaceuticals is ₹28100.3 Cr As on 06 February, 2026 | 04:51

The P/E ratio of Emcure Pharmaceuticals is 32.3 As on 06 February, 2026 | 04:51

The PB ratio of Emcure Pharmaceuticals is 5.9 As on 06 February, 2026 | 04:51

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23